Cargando…
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
PURPOSE: Tenosynovial giant cell tumor (TGCT), a rare locally aggressive neoplasm of the synovium of joints and tendon sheaths, is associated with joint destruction, inflammation, pain, and swelling, in part due to colony-stimulating factor 1 receptor–bearing macrophages recruited to the tumor by ge...
Autores principales: | Gelhorn, Heather L., Tong, Sandra, McQuarrie, Kelly, Vernon, Christina, Hanlon, Jennifer, Maclaine, Grant, Lenderking, William, Ye, Xin, Speck, Rebecca M., Lackman, Richard D., Bukata, Susan V., Healey, John H., Keedy, Vicki L., Anthony, Stephen P., Wagner, Andrew J., Von Hoff, Daniel D., Singh, Arun S., Becerra, Carlos R., Hsu, Henry H., Lin, Paul S., Tap, William D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469507/ https://www.ncbi.nlm.nih.gov/pubmed/27041409 http://dx.doi.org/10.1016/j.clinthera.2016.03.008 |
Ejemplares similares
-
The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS)
por: Gelhorn, Heather L., et al.
Publicado: (2019) -
Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022) -
Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial
por: Van De Sande, Michiel, et al.
Publicado: (2021) -
Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020) -
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)